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1. Introduction 
Cervical cancer is the best known example of a common human malignancy with a proven 
infectious etiology. Clinical, epidemiological and molecular analyses have long indicated 
that persistent infection with high-risk human papillomaviruses (HPVs) is causally 
associated with cervical cancer. Although new prophylactic vaccines and highly sensitive 
HPV typing methods are currently available, cervical cancer continues as the most common 
tumor in developing countries, where most of the annual half a million new cases occur 
(Arbyn et al., 2011). Besides socio-cultural issues restraining professional gynecological care, 
the relatively high cost of these technologies has limited their availability where they are 
most needed. Thus, there is a pressing need for affordable and readily available detection 
and therapeutic tools for HPV infection and cervical cancer. In the last two decades, novel 
diagnostic and therapeutic approaches based on synthetic oligonucleotides and genomic 
information have developed into promising tools to fight human disease. 
2. HPV and cervical cancer 
Genital dysplasia and cervical cancer are associated with persistent infection of a subset of 
HPVs referred as high-risk, including HPV types 16, 18, 31, 33, 45, 52 and 58 (Clifford et al., 
2003). High-risk HPVs normally replicate in keratinocytes from stratified squamous 
epithelia of their hosts where the 8-kb double-stranded circular DNA genome is usually 
retained in an episomal form. The highly conserved high-risk HPV genomes consist of six 
common early genes (E1, E2, E4, E5, E6 and E7) and two late genes (L1 and L2) coding for 
the capsid proteins (Figure 1). The early genes contribute to cellular transformation, viral 
regulation and DNA replication (Moody & Laimins, 2010). In addition, the HPV genome 
also comprises a highly variable non-coding regulatory region, the long control region 
(LCR), which contains the viral origin of replication and regulatory elements targeted by 
several cellular transcription factors and the viral E2 gene (Hebner & Laimins, 2006).  
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Fig. 1. Map of the HPV genome. Early (E) and ate (L) genes are indicated. The arrow 
indicates the early promoter. 
2.1. HPV targets for diagnostic and therapeutic oligonucleotides 
The relationship between cervical cancer and high-risk HPVs is related to the integration of 
viral DNA to the host genome with the disruption of the viral regulator E2 (Pett & Coleman, 
2007; Vernon et al., 1997), and to the production of viral proteins E6 and E7 which are 
sufficient and necessary to acquire and maintain a transformed phenotype (Pirisi et al., 1988; 
Xue et al., 2010). Because E2 is usually absent in cervical tumor cells and E6/E7 genes are 
retained and expressed in most tumors, these features are often referred to as the hallmarks 
of cervical cancer (Alvarez-Salas & DiPaolo, 2007). In the absence of E2 protein, high-risk 
HPV E6 and E7 genes are continuously transcribed from a single promoter resulting in 
polycistronic mRNA containing both transcripts (Wang et al., 2011). The E6 and E7 protein 
products interact and functionally neutralize key cellular regulatory proteins, so that cell 
proliferation continues. 
High-risk HPV E6 protein targets numerous cellular pathways to insure viral DNA 
replication and is a key oncogene in HPV associated neoplasias. E6 was first shown to 
interact with the p53 tumor suppressor protein (Werness et al., 1990) and the E6-AP complex 
to act as a ubiquitin protein ligase (Huibregtse et al., 1991) inducing the specific 
ubiquitination and degradation of p53 (Scheffner et al., 1993). Thus, high-risk HPV E6 
results in blockage of p53-mediated apoptosis. Interestingly, E6 has been found interacting 
with the extrinsic apoptotic factors TNFR-1, FADD and caspase-8 (Filippova et al., 2002; 
Tungteakkhun et al., 2010) suggesting alternative apoptosis inhibitory functions. Although 
E6-mediated degradation of p53 is considered a key event for the onset of cellular 
transformation, it is clear that E6 possess other p53-independent transforming and anti-
apoptotic activities, such as telomerase activation (Gewin et al., 2004; Klingelhutz et al., 
1996; Oh et al., 2001). Many other cellular targets of high-risk E6 proteins have now been 
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described, including PDZ domain-containing targets such as the human homologue of the 
tumor suppressor DLG (discs large protein) (Gardiol et al., 1999), MUPP1 (Lee et al., 2000) 
and MAGUK (membrane-associated guanylate kinase) proteins  (Glaunsinger et al., 2000), 
and a number of transcription regulators (Etscheid et al., 1994; Zimmermann et al., 1999), 
disrupting cell adhesion, polarity, epithelial differentiation and  reducing  immune  
recognition  of  HPV infected cells (Howie et al., 2009).  
The E7 protein plays a vital role in the viral life cycle by disrupting the tight link between 
differentiation and proliferation, thus allowing viral replication in normal keratinocytes that 
would be otherwise withdrawn from the cell cycle (McLaughlin-Drubin & Munger, 2009). 
E7 protein from high-risk HPVs targets pRB and disrupts the E2F-mediated transcriptional 
regulation resulting in the up-regulation of genes required for G1/S transition and DNA 
synthesis (Duensing et al., 2001; Munger & Phelps, 1993).  HPV-16 E7 can directly bind the 
G1/S transition antagonists E2F1  (Hwang et al., 2002) and E2F6 (McLaughlin-Drubin et al., 
2008) thus ensuring that the infected cells remain in an S-phase-competent  state  allowing 
HPVs to bypass negative growth signals. The steady-state level and metabolic half-life of 
pRB are decreased in HPV-16 E7-expressing cells, because E7 can induce the degradation of 
pRB through the ubiquitin-proteasome system (Berezutskaya et al., 1997; Boyer et al., 1996). 
High-risk HPV E7 proteins also contribute to cell cycle dysregulation through the 
abrogation of the growth inhibitory activities of p21CIP1 and p26KIP1 (Funk et al., 1997; Jones 
et al., 1997; Zerfass-Thome et al., 1996). Other functions associated to high-risk HPV 
expression include epigenetic reprogramming through induction of KDM6A and KDM6B 
histone demethylases (McLaughlin-Drubin et al., 2011), trophic sentinel signaling 
abrogation and autophagy induction (Zhou & Munger, 2009), induction of genomic 
instability (Duensing et al., 2000), and disruption of Anoikis signaling through interaction 
with p600 (Huh et al., 2005). 
3. Oligonucleotide applications to cervical cancer and HPV infection 
Although the independent E6 and E7 functions may cause genomic instability, cell 
immortalization and transformation by themselves, the unregulated expression of both 
proteins is considered the major contribution of HPVs to cervical cancer development. The 
demonstration of the existence of stable molecular targets in high-risk HPVs has justified the 
development of small oligonucleotides for cervical cancer detection and treatment. High-
risk HPV-16 and 18 express E6 and E7 proteins from a single polycistronic mRNA 
(Schneider-Gadicke & Schwarz, 1986; Smotkin et al., 1989), suggesting that  targeting of 
either E6 or E7 mRNA would likely impede both E6/E7 translation resulting in similar 
growth arrest phenotypes. Several groups have identified that inhibition of these genes 
translation resulted in tumor growth suppression confirming E6/E7 as attractive targets for 
cervical cancer therapy (Alvarez-Salas et al., 1998; Shillitoe, 2006; Venturini et al., 1999). 
In the last decades, novel therapeutic approaches based on genomic information developed 
into promising tools to fight human disease. Therapeutic oligonucleotides are short DNA or 
RNA molecules designed to disrupt expression or function of disease-related genes. 
Approaches to therapeutic oligonucleotide technology include: 1) Blocking of gene 
transcription by triplex-forming oligodeoxyribonucleotides (TFOs); 2) Translation inhibition 
by AS-ODNs, small interfering RNAs (siRNAs) and ribozymes; 3) Inhibition of protein 
function by nucleic acid aptamers and 4) Immunostimulatory oligonucleotides (IM-ONS) 
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(Alvarez-Salas, 2008). Diagnostic oligonucleotides refer to the application of DNA or RNA 
oligonucleotides for diagnostic purposes. Diagnostic oligonucleotide technologies comprise 
oligonucleotides designed for 1) Priming polymerase chain reaction (PCR or RT-PCR) 
detection, 2) Hybridization-based technologies (hybrid capture or microarrays) and 3) 
Binding with target proteins (aptamers). Here, we will only discuss diagnostic 
oligonucleotides used as aptamers for HPV detection because PCR and hybridization 
technologies have been extensively used for HPV diagnostics for decades and the subject 
has been comprehensively analyzed elsewhere (Stanley, 2010).   
3.1 Antigene technology 
TFOs can hybridize with particular sequences in double-stranded DNA (dsDNA) through 
the formation of Hoogsteen or reverse-Hoogsteen hydrogen bonds between the TFOs and 
homopurine stretches found in the major groove of the target DNA (Letai et al., 1988; Moser 
& Dervan, 1987). TFOs have potential for manipulating gene structure and function in living 
cells, inhibiting transcription by interfering with regulatory protein binding or blocking 
mRNA elongation (Carbone et al., 2003) (Figure 2A). Although finding appropriate targets 
for TFO action in genomic DNA may be an issue, TFO technology has a potential advantage 
over oligonucleotide-based control of translation (antisense and siRNA technologies) 
because there are generally one to two targets per cell as compared with the hundreds to 
thousands copies of mRNA targets (Vasquez & Glazer, 2002).  
 
       A                     B 
Fig. 2. A) Antigene technology. Triplex-forming oligonucleotides (TFOs) hybridize with 
DNA to block transcription. B) Antisense oligonucleotides (AS-ODNs) gene silencing. As-
ODNs hybridize with the 5’-UTR (1) or within the coding region (2) of the target mRNA. 
Formation of DNA-RNA heteroduplexes induces RNaseH (3) activity over the RNA target 
(3a) producing degradation and thus inhibiting translation. Stable hybridization with the 
target 5’-UTR mRNA can inhibit ribosome anchorage (4).  
3.1.1 Antigene technology on cervical cancer 
Several natural triplex-forming sites have been identified within the HPV-16 genome 
(Malkov et al., 1993). However, only a few attempts have been reported on the use of TFOs 
against HPV. An initial report for the low-risk HPV-11 established an intramolecular triplex 
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DNA formation using a TFO directed to a 22nt-long homopurine stretch within the LCR (nt 
21-42) overlapping a Sp-1 and a E2 binding site plus the origin of replication. Although the 
stability of the triplex DNA formation was comprehensively demonstrated, no functional 
effect on HPV-11 transcription/replication was reported (Hartman et al., 1992). Other report 
also established formation of pyrimidine-purine-pyrimidine or pyrimidine-purine-purine 
triplex DNA with the HPV-16 fragment nt 554-685 under favorable conditions using 
complementary pyrimidine or purine TFOs. The observed DNA triplexes exhibited 
remarkable sequence specificity (Cherny et al., 1993). 
Optical DNA melting experiments and co-migration assay were used to establish stable 
triplex DNA formation at homopurine-homopyrimidine-rich target sites present in the 
HPV-16 E7 gene (nt 656-673). The target sequence was specifically recognized by several 17-
mer purine TFOs designed to form antiparallel or parallel triplex DNA helices (Popa et al., 
1996). Despite the reported success on triplex DNA formation using TFOs and different 
HPV targets, there are no reports on the application of TFOs to inhibit HPV transcription 
suggesting that intracellular conditions may not allow effective antigene-based therapies. 
3.2 The antisense approach 
Antisense inhibition uses DNA sequence information to synthesize an oligonucleotide 
complementary to a target mRNA and specifically inhibit or modify translation by three 
main mechanisms: A) Translational arrest by inhibiting ribosome binding at the 5’-UTR 
(Crooke, 1999); B) Induced degradation of the target mRNA by RNaseH (Agrawal et al., 
1990) (Figure 2B), and C) Translational modulation by exon-skipping (Du & Gatti, 2009). The 
aim of all antisense approaches is to reduce the quantity of the target protein in order to 
revert or prevent progression of a disease process.  
Two main classes of antisense oligonucleotides have been used to silence or modulate gene 
expression providing that the target sequences are exposed (in a single stranded form 
lacking secondary structure or protein binding). One class makes use of AS-ODNs 
complementary to the target mRNA. AS-ODN hybridization to its complementary target 
mRNA by Watson–Crick base pairing should provide enough specificity and affinity to 
produce translational arrest (physical blockage of ribosome binding) of the target mRNA. 
Additionally, the formation of DNA-RNA heteroduplexes leads to the activation of RNaseH 
thus inducing cleavage of the target mRNA (Bonham et al., 1995). The second antisense 
oligonucleotide technology class consists of small, catalytic RNA or DNA molecules. The 
catalytic core of these molecules produces cleavage of a target RNA once the catalytic 
moiety has hybridized with a Watson-Crick complementary sequence (Benitez-Hess & 
Alvarez-Salas, 2006). This mechanism may be contrasted with AS-ODNs that require 
cellular RNaseH activity following hybridization in order to cleave the target mRNA. 
3.2.1 AS-ODNs applications as therapeutic moieties 
Early use of unmodified AS-ODNs showed that they were highly unstable in biological 
fluids due to the presence of exonucleases thus limiting their use as therapeutic moieties. 
Later, several nucleotide analogues were introduced to increase ODN stability. To avoid 
changes in hybridization specificity, modifications were limited to the phosphate and ribose 
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backbone of DNA/RNA oligonucleotides. First generation modified AS-ODNs consisted of 
sulfur-substituted DNA on the free oxygen molecules constituting a phosphodiester bond. 
Phosphorothioated ODNs (PS-ODNs) display a high degree of stability in biofluids while 
retaining the ability to form RNaseH substrates leading to efficient, highly specific 
degradation of the target mRNA (Agrawal & Zhang, 1997). RNaseH activity is mostly 
nuclear and thus would likely produce cleavage of the pre-mRNA within the nucleus before 
splicing (Wagner et al., 1993). However, the strongly polyanionic nature of PS-ODNs cause 
in vivo issues regarding affinity, specificity, cellular uptake, biodistribution and toxicity thus 
limiting their therapeutical use (Akhtar & Agrawal, 1997). Nevertheless, PS-ODNs have 
been the most extensively studied AS-ODNs in various animal models and humans leading 
to oligonucleotide-based drugs such as Fomivirsen (Vitravene™) or Affinitak (Patil et al., 
2005).  
The use of other modifications such as methylphosphonates, ethylphosphonates or 2'-O-
methyl, confer high affinity for target sequences and extraordinary stability in biofluids, but 
they do not activate RNaseH (Mercatante & Kole, 2000). Thus, these modifications are better 
suited for modulating gene expression or exon-skipping approaches rather than gene 
silencing (Sierakowska et al., 2000). Second-generation AS-ODNs provide molecules with 
RNaseH activity but minimal off-target effects. Mixed-backbone oligodeoxynucleotides 
(MBOs) contain strategically placed segments of phosphorothioated backbones (able to 
induce RNaseH activity on the target mRNA) mixed with segments of either modified 
oligodeoxyribonucleotides or oligoribonucleotides (reducing off-target effects). The 
advantages of MBOs over PS-ODNs are increased biological activity, reduced polyanionic- 
and CG-dinucleotide-related side effects and increased in vivo stability (Agrawal & Zhao, 
1998). A third-generation AS-ODNs contains DNA/RNA oligonucleotides with 2'-O-methyl 
modification in addition to a phosphorothioate core and methylphosphonate ends further 
reducing toxicity. Improved stability, high specificity and low toxicity characterize these 
molecules, allowing for efficient destruction of target mRNA at nanomolar concentrations 
(Sternberger et al., 2002).  
3.2.2 Antisense technology on cervical cancer therapy  
Earlier reports on high-risk HPV E6 and E7 functions used plasmid-borne full-length antisense 
RNA to show that inhibition of HPV-18 E6/E7 expression results in growth arrest in C4-1 cells 
(von Knebel Doeberitz & Gissmann, 1987; von Knebel et al., 1988). Later, plasmid-borne 
antisense RNA delivery was shown to induce apoptosis in CaSki cells via up-regulation of p53 
and apoptosis induction (Cho et al., 2002). Delivery of antisense RNA using adenoviral vectors 
and retroviral vectors on SiHa and CaSki cells resulted in the reduction of HPV16 E7 protein 
expression and cell proliferation. These changes were accompanied by cell cycle arrest, up-
regulation of RB, down-regulation of E2F-1 and BCL-2 and dose-dependent and retarded 
tumor growth of CaSki cells, a cervical cancer line with multiple copies of HPV-16 (Choo et al., 
2000; Hayashi et al., 1997). More recently, non-neuroinvasive HSV-1 vectors, lacking the γ134.5 
gene, were used to express antisense RNA complementary to the first 100nt of the HPV-16 E7 
gene. These recombinant viruses down-regulated E7 protein expression in CaSki cells in a 
dose-dependent manner (Kari et al., 2007). Overall, these results confirmed the validity of 
targeting high-risk HPV E6/E7 for cervical cancer therapy. Nevertheless, due to the difficulties 
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of administrating plasmids, large antisense RNA molecules or even infectious viruses to 
patients, the use of small antisense moieties such as AS-ODNs, catalytic oligonucleotides or 
siRNAs might be a better alternative.  
Pioneering attempts on E6/E7 targeting by AS-ODNs directed antisense PS-ODNs to the 
translational start site of E6/E7 mRNA (Steele et al., 1993; Tan & Ting, 1995). In vivo testing 
on CaSki, SiHa and HeLa cells (all cervical cancer cell lines containing high-risk HPV) 
showed that these PS-ODNs produced cell growth inhibition. Nevertheless, no data was 
provided to show growth inhibition due to a true antisense mechanism. Later, a rational 
approach to antisense exposed regions was applied to HPV-16 E6/E7 using fast-hybridizing 
RNA segments obtained from partially digested E6/E7 mRNA (Kronenwett & Sczakiel, 
1997). A selection of AS-ODNs directed against such exposed sequences resulted in growth 
inhibition of cultured SiHa cells (Venturini et al., 1999).  
Our group developed AS-ODNs covering a so-called "antisense window" within a stable 
HPV-16 E6 (nt 410-445) region (Alvarez-Salas et al., 1995). Two short antisense PS-ODNs 
complementary to nt 410-445 produced efficient growth inhibition of monolayer and agar-
growth HPV-16-containing tumor cell lines in a dose-dependent manner. One of such PS-
ODNs also inhibited tumor growth in nude mice (Alvarez-Salas et al., 1999; Marquez-
Gutierrez et al., 2007). Interestingly, the combined use of both AS-ODNs resulted in the 
additive but not synergistic growth inhibition suggesting that they can be applied together 
to overcome issues related to genital HPV genomic variability (Marquez-Gutierrez et al., 
2007). Nevertheless, the high doses used in these studies (within the micromolar range) 
suggest that further modifications are required to improve therapeutical efficiency avoiding 
off-target effects. Overall, current AS-ODN applications to high-risk HPV E6/E7 gene 
silencing as a therapy for cervical cancer appears promising and relatively safe, providing 
that the tested PS-ODNs are administered locally to control off-target issues commonly 
observed with phosphorothioated moieties. Nevertheless, second and third-generation AS-
ODNs remain to be clinically tested as the advancement of other gene silencing technologies 
(i.e. siRNA and shRNAs) overcame an otherwise very effective molecular therapy.  
3.3 Therapeutic catalytic oligonucleotides 
Small ribozymes and DNAzymes are oligonucleotides possessing, at the very least, 
enzymatic RNA cleavage and ligation activities (Haseloff & Gerlach, 1988; Santoro & Joyce, 
1998). Ribozymes were initially described as catalytic RNA moieties found in the self-
splicing group I introns from the unicellular algae Tetrahymena (Kruger et al., 1982), and 
within the RNA active site of Escherichia coli RNaseP (Guerrier-Takada et al., 1983). 
However, the relatively large size of these two ribozymes precluded gene 
modulating/silencing applications. Later, small catalytic RNA cores from naturally 
occurring ribozymes were isolated from the circular genomes of certain pathogenic plant 
RNA viroids (Haseloff & Gerlach, 1989). In particular, two catalytic moieties have been 
intensely used as therapeutic agents; the hammerhead and hairpin ribozymes. By simply 
altering the native substrate recognition sequences, natural cis-cleaving ribozymes can be 
engineered to recognize and cleave any target RNA in trans by Watson-Crick hybridization 
(Michienzi & Rossi, 2001) (Figure 3A). Consequently, ribozymes received considerable 
attention as potentially valuable tools for the inhibition of virus replication, modulation of 
tumor progression, and analysis of cellular gene function (Morrissey et al., 2002). 
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        A               B 
Fig. 3. A) Catalytic oligonucleotides mode of action. Ribozymes or DNAzymes hybridize 
and cleave the target mRNA. B) RNA interference (RNAi) mechanism. Double-stranded 
RNA (dsRNA) found in a given mRNA are recognized and cleaved by DICER to yield small 
interfering RNAs (siRNAs) that in turn are incorporated into the RISC complex to cleave the 
mRNA from which they were derived. By administrating synthetic siRNAs the RISC 
complex may be manipulated to target a particular mRNA. 
3.3.1 The hammerhead ribozyme 
Hammerhead ribozymes are small (30-40nt) catalytic RNA moieties composed of three basic 
components including a highly conserved catalytic domain flanked by two base-pairing 
sequences and a complementary sequence within the target RNA containing the sessile 
phosphodiester bond. Natural catalytic centers can be formed within contiguous RNA 
sequences or by sequences several nucleotides apart (Epstein & Gall, 1987; Hutchins et al., 
1986). Providing that the target RNA is single-stranded, hammerhead ribozymes can cleave 
any substrate RNA containing the triplet 5´-NUX-3´, where U is conserved, N is any 
nucleotide and X can be C, U or A (Vaish et al., 1998). Cleavage occurs 3’ to the 5’-NUX-3’ 
triplet (Uhlenbeck, 1987), generating 5’ hydroxyl termini and a 2’,3’-cyclic phosphate at the 
cleavage site (Hutchins et al., 1986; Prody et al., 1986).  
3.3.2 The hairpin ribozyme 
Hairpin ribozymes are about 60nt long and efficiently catalyze a reversible, site-specific 
cleavage reaction. Structurally, hairpin ribozymes are composed by the substrate recognition 
domain A located aside the catalytic domain B and the target RNA containing the target site. 
The established cleavage requirements for heterologous substrates indicate that the substrate 
sequence must contain a 5’-BN*GUC-3’ motif (where * is the site of cleavage) (Anderson et al., 
1994; Hampel et al., 1990). Cleavage occurs at the 5’ side of guanosine and yields two products: 
the 3’-product containing the 5’-hydroxyl terminus newly formed within a terminal G, and the 
5’-product containing the 2’,3’-cyclic phosphate (Yu & Burke, 1997).  
3.3.3 Catalytic DNA 
DNAzymes are small (~30nt) catalytic DNA oligonucleotides capable of cleaving target 
RNA molecules in a sequence specific manner (Baum & Silverman, 2008). These molecules 
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represent a new generation of catalytic oligonucleotides artificially obtained through in vitro 
selection procedures by their capacity to catalyze the cis-cleavage of a target RNA sequence. 
Similar to ribozymes, DNAzymes hybridize substrate RNAs by Watson-Crick pairing and 
cleavage results in RNA fragments containing 2’,3’-cyclic phosphate and 5’-hydroxyl ends, 
suggesting a common mechanism (Santoro & Joyce, 1998). Therefore, the same widely tested 
design rules for AS-ODNs and ribozymes can be readily applied for therapeutic 
DNAzymes. However, unlike ribozymes, usage of DNAzymes as therapeutic moieties has 
the advantage of simpler and cost-effective synthesis, easier administration and higher 
stability in biofluids (Dass et al., 2008). So far, the 10-23 DNAzyme is the most commonly 
used in therapeutic applications. The 10-23 moiety structure resembles that of a 
hammerhead ribozyme consisting of a 15nt catalytic core flanked by two target recognition 
arms complementary to the target RNA (Santoro & Joyce, 1997). Cleavage is strictly 
dependent on Mg++ and is specifically produced at a RY (R, purine; Y, pyrimidine) junction 
within the target RNA  (Cairns et al., 2003; Faulhammer & Famulok, 1997). Although the 10-
23 DNAzyme is active at 37°C it may require nucleotide modifications to keep high activity 
under physiological conditions (Takamori et al., 2005). Other DNAzymes with different 
structural and catalytic features have been successfully used as sensors for ions, molecules 
and even proteins (Ali et al., 2011; Zhang et al., 2011). Thus, DNAzymes offer a wide array 
of possible therapeutical and diagnostic applications. 
3.3.4 Hammerhead ribozymes and HPV 
Early reports on ribozyme use against HPV assumed that translational start regions within 
mRNA are poorly structured thus allowing accessibility to antisense moieties. These reports 
were limited to cell-free experimentation and characterization of ribozyme cleavage on HPV 
target transcripts. Hammerhead ribozymes directed to HPV-16 nt 110 and 558 and 
expressed from plasmids showed efficient cleavage of HPV-16 E6/E7 transcripts in cell-free 
tests in different conditions of ionic strength, Mg++ concentration and temperature. 
Evaluation of the simultaneous activity of both ribozymes suggested a cooperative effect to 
disrupt HPV-16 E6/E7 gene expression (Lu et al., 1994). Similarly,  targeting HPV-16 E6/E7 
genes by hammerhead ribozymes specific to nt 240 and 597 showed that target size is 
important for catalytic activity (He et al., 1993). Chen et al., developed hammerhead 
ribozymes targeting HPV-18 E6/E7 genes (nt 120, 309 and 671) that were initially tested by 
incubation of total RNA from HeLa and Vero cells with in vitro transcribed ribozymes 
resulting in the efficient and specific degradation of HPV-18 transcripts from HeLa cells. In a 
more unorthodox approach E. coli was used to co-expresses both the ribozymes and a 1266nt 
fragment from HPV-18 (including E6 and E7 genes). Ribozymes were induced by infection 
with a helper phage (T7/M13) resulting in the progressive down-regulation of the HPV-18 
target. Finally, ribozyme anti-tumor activity was tested on HeLa cells resulting in a cell 
growth reduction, increased serum dependency, and reduced foci formation in soft agar 
(Chen et al., 1996; Chen et al., 1995) .  
3.3.5 Hairpin ribozymes and HPV 
Hairpin ribozymes are usually more efficient at 37°C than hammerhead ribozymes and co-
factors are not a strict requirement for activity because the catalytic mechanism appears to 
rely on structural components (Walter et al., 1998). However, efficient cleavage by hairpin 
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ribozymes requires a specific sequence within the target RNA (5’-GUC-3’ motif). We 
performed a comprehensive search for hairpin ribozyme target sites within HPV-16 E6/E7 
genes showed six potential target sites. A hairpin ribozyme directed to site 434 (R434) was in 
vivo tested for cis-cleavage using a plasmid-borne HPV-16 E6/E7 transcripts containing 
ribozymes at the 3’-UTR. Only R434-containig transcripts caused significant delay in the 
growth rate of transfected cells and inhibited E6/E7 immortalization (Alvarez-Salas et al., 
1998). Although this report demonstrated the feasibility of hairpin ribozyme use as a 
therapeutic antisense moiety for cervical cancer, the larger size of hairpin ribozymes limited 
their application as plasmid-borne moieties. Thus, we developed multiplex expression 
systems (triplex) based on hairpin ribozymes for R434. Such systems resulted in the 
complete release of multiple independent catalytic units from a single transcript by a self-
processing mechanism, allowing individual R434 activity and increasing efficiency of 
degradation of E6 RNA (Aquino-Jarquin et al., 2008; Aquino-Jarquin et al., 2010). The 
measured activity of a single R434 unit resulted in 30% inhibition of HPV-16 E6/E7 mRNA 
in SiHa cells, suggesting that multiple ribozymes directed against the same or other target 
sites might result in complete inhibition (Aquino-Jarquin et al., 2008). 
It is worth mentioning that notwithstanding the relative success on inhibiting HPV E6/E7 
by ribozymes, the catalytic features from both hammerhead and hairpin ribozymes 
dramatically drop within the cellular environment. Intracellular variables affecting activity 
include Mg++ availability, co-localization with the target, nuclease action and protein 
binding (Benitez-Hess & Alvarez-Salas, 2006). Plasmid-borne ribozymes usually contain 
stem-loop or tRNA structures to extend intracellular life that may get targeted by several 
RNA-processing mechanisms thus impeding activity (Alvarez-Salas L.M., unpublished data). 
Alternatively, because of their small size (~30nt) hammerhead ribozymes may be 
synthesized including modified nucleotides to escape nuclease and RNA processing 
mechanisms but this alternative usually brings deleterious off-target effects that may 
mislead data interpretation and limit clinical application. The therapeutical use of ribozyme 
in cervical cancer has never approached to the simple, efficient and relatively safe use of AS-
ODNs. Therefore, because the proven high ribozyme specificity and catalytic features for 
HPV transcripts it is likely that ribozymes may be better suited for diagnostic usage in 
cervical cancer. 
3.3.6 DNAzymes on cervical cancer therapy 
DNAzymes have become one of the most versatile oligonucleotide technologies available. In 
the last few years, DNAzymes have been used as therapeutical agents, computing DNA, 
biochemical analysis tools and sensors (Baum & Silverman, 2008; Stojanovic et al., 2005). 
However, there are only a few reports on DNAzyme application in the fields of cervical 
cancer and HPV. Our first report on a modified 10-23 DNAzyme directed to HPV-16 E6/E7 
mRNA “antisense window” showed efficient down-regulation of E6/E7 transcripts both in 
vitro and in vivo resulting in specific inhibition of proliferation and cell death in a dose-
dependent manner (Reyes-Gutierrez & Alvarez-Salas, 2009). To improve efficiency and 
intracellular stability the DNAzyme was modified with locked nucleic acids (LNAs) 
producing more thermostable DNAzyme-RNA complexes resulting in better cleavage 
efficiency (Benitez-Hess et al., 2011). In our hands, DNAzyme technology merged the 
relative simplicity and affordability of DNA synthesis and modification with the expected 
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benefits of enzymatic catalysis yielding a therapeutical moiety superior in performance and 
specificity when compared to AS-ODNs and even siRNAs at the nanomolar range. 
3.4 The small RNA revolution: siRNAs, shRNAs and miRNAs 
The mechanism of RNA interference (RNAi) is a natural and wide-spread gene knockdown 
phenomenon induced by the formation of double-stranded RNA (dsRNA) segments in most 
mRNAs (Elbashir et al., 2001; Fire et al., 1998; Sharp, 1999). The RNAi process occurs in the 
cytoplasm where dsRNA regions within mRNAs are digested into double-stranded 21–23nt 
fragments, with a 2nt 3’-overhand, by the RNaseIII-like enzyme DICER (Bernstein et al., 
2001). Subsequently, these small fragments, now called small interfering RNAs or siRNAs, 
are denatured by a helicase and one strand (leader or guide strand) is then incorporated into 
an RNA-induced silencing complex (RISC) that includes DICER, AGO2, TRBP and other 
members of the Argonaute family (Cullen, 2006; Hammond et al., 2001; Meister et al., 2004; 
Nykanen et al., 2001). The activated RISC complexes containing the guide strand hybridize 
and cleave the homologous mRNA from which they were derived. Therefore, there are no 
genes coding for particular siRNAs (Bartel, 2004). Recent reports suggest that siRNA activity 
exhibit serious dependence on the target site, as is the case for other antisense-based 
technologies, which might significantly limit the convenient use of siRNA (Miyagishi et al., 
2003). Target recognition by activated RISC complexes appear to rely on the perfect 
matching between the target sequence and a 2-8nt region within the guide strand known as 
“seed” region (Lin et al., 2005).  
By using synthetic siRNAs administrated exogenously, the RNAi machinery can be 
manipulated to silence a given mRNA (Figure 3B). These siRNAs can bypass the earlier 
steps in the RNAi pathway and can be loaded directly onto the RISC complex. Both 
synthetic siRNAs and vector-borne delivery of the equivalent short hairpin RNAs (shRNAs) 
have been used as potential therapeutic moieties for cervical cancer. Because shRNAs rely 
on the vector used, we will only focus in the developments of siRNAs as true therapeutic 
oligonucleotides. Although powerful, the widely reported gene silencing effects of siRNAs 
do not appear specific in many instances as down-regulation of unintended targets with 
partial sequence complementarities and stimulation of innate immune by type I interferon 
(IFN-I) and/or inflammatory cytokine responses have been often reported (Jackson et al., 
2003; Judge et al., 2005; Kalali et al., 2008).  
On the other hand, miRNAs are also small 20–25nt long non-coding dsRNAs with very 
specific functions modulating gene expression by hybridizing to complementary sequences 
present in the 3′ UTR of many protein-coding mRNAs (Bartel, 2004). Unlike siRNAs, the 
miRNAs are coded in the genome of most metazoans (including humans) by independent 
loci or within intronic regions of other genes (Cullen, 2004; Kim & Kim, 2007). They are 
initially transcribed by the RNA polymerase II as primary miRNAs (pri-miRNAa) (Lee et al., 
2004), which are cleaved into pre-miRNA hairpins by the RNaseIII-like nuclease DROSHA 
and PASHA/DGCR8 (Gregory & Shiekhattar, 2005). Pre-miRNAs are exported from the 
nucleus by the EXPORTIN-5  (Yi et al., 2003). Intronic pre-miRNAs are generated as a 
product of splicing of the host gene (Berezikov et al., 2007). Once in the cytoplasm, the pre-
miRNA hairpins merge to the RNAi pathway and are cleaved by DICER to produce mature 
miRNAs that are incorporated into RISC and interact with their targets (Valencia-Sanchez et 
al., 2006).  
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3.4.1 RNAi therapeutics on HPV 
Early attempts to silence high-risk HPV gene expression using siRNAs indicated selective 
E6/E7 mRNA. E6 silencing by a siRNA directed to HPV-16 nt 224-242 induced 
accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and 
reduced cell growth but no apoptosis. Surprisingly, E7 silencing produced by a siRNA to nt 
662-680 induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-
viral siRNAs (Jiang & Milner, 2002). Because the polycistronic expression of HPV-16 E6 and 
E7 both siRNAs would have similar effect on E6/E7 expression and thus similar phenotypes 
(Butz et al., 2000). Although no explanation has been provided for this puzzling result, it is 
likely that the reported observations may be related to off-target effects. 
Later it was reported that vector-borne and synthetic siRNAs directed against the HPV-18 
E6 gene (nt 385-403) restored dormant tumor suppressor pathways in HPV-positive cancer 
cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive 
apoptotic cell death, selectively in HPV-positive tumor cells (Butz et al., 2003). More recently 
a siRNA molecule targeting the E7 region of the bicistronic HPV-18 E6 and E7 mRNA (nt 
142-160) reduced expression of E6 and E7 in HeLa cells. Application of siRNAs against E6 
and E7 also inhibited cellular DNA synthesis and induced morphological and biochemical 
changes characteristic of cellular senescence. These results demonstrate that reducing E6 
and E7 expression is sufficient to cause HeLa cells to become senescent thus establishing 
that targeting of E6/E7 mRNA affects synthesis and functions of both E6 and E7  (Hall & 
Alexander, 2003). The simultaneous targeting of HPV-18 E6/E7 has also been reported to 
induce apoptosis and reduce proliferation of HeLa cells (Qi et al., 2010). Interestingly, it has 
been shown that cellular apoptosis induced by siRNA directed to HPV-18 E6 in HeLa cells 
relies on the p53 and ubiquitin proteolysis pathway thus inhibiting cell proliferation and 
promoting cell apoptosis. Anti-oncogene and upper regulation of immunization-related 
genes produced regression of the malignant phenotype after E6 inhibition (Min et al., 2009). 
Other synthetic siRNA decreased the levels of HPV-16 E6/E7 mRNA and induced nuclear 
accumulation of p53 in SiHa cells. The siRNA also suppressed monolayer and anchorage-
independent growth associated with p21CIP1/WAF1 induction and hypophosphorylation 
of retinoblastoma protein. Furthermore, SiHa cells treated with the anti-E6 siRNA prior to 
subcutaneous injection, formed tumors in NOD/SCID mice that were significantly smaller 
than in those treated with a control siRNA (Yoshinouchi et al., 2003). Thus, sequence-
specific targeting of high-risk HPV E6/E7genes, siRNAs may be developed into novel 
therapeutics that can efficiently inhibit growth of cervical cancer cells. Nevertheless, in vivo 
delivery of siRNAs is still a major obstacle to their clinical use.  
As with other oligonucleotide-based therapeutical approaches, in vivo delivery of siRNA is 
mostly affected  by ribonuclease degradation, rapid  renal  excretion  and  nonspecific  
uptake  by  the reticuloendothelial  system (Whitehead et al., 2009). Additionally, siRNAs 
are polyanions that do not readily cross the cell membrane. In turn to avoid these issues, 
siRNAs are often synthesized with phosphorothioated or 2’-O-modified bases and 
encapsulated in delivery systems allowing enhanced stability in biofluids and cell uptake, 
escape immune recognition, and improve pharmacokinetics by avoiding excretion and renal 
filtration (Lorenz et al., 2004; Sorensen et al., 2003). Encapsulated siRNAs still need to  
co-localize with the appropriate target cell/tissue type leading to more complicated 
therapeutic strategies. Thus, several considerations regarding biodistribution, extracellular 
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and intracellular transport must be addressed in addition to potency and biostability before 
clinical use of siRNAs. Nevertheless, the recent success in clinical trials using siRNA to treat 
age-related macular degeneration (Bevasiranib), respiratory syncytial virus infection (ALN-
RSV01) and the targeted in vivo gene silencing via systemic delivery of siRNA using 
transferrin-tagged, cyclodextrin-based nanocapsules for human cancer therapy (CALAA-01) 
have demonstrated the therapeutic feasibility of siRNAs (Shim & Kwon, 2010).  
In the last few years, siRNA use for silencing high-risk HPV E6/E7 has been widely 
reported although emphasis shifted from design and targeting to delivery and specificity, as 
highly active siRNAs are now commercially available. Many reports showed successful 
E6/E7 inhibition, but most of them were limited to cell culture, lacking of toxicity controls 
(Jonson et al., 2008; Lea et al., 2007; Sima et al., 2008; Yamato et al., 2008). A recent report, 
undertook a more comprehensive approach by designing and testing nine different siRNAs 
against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations. The siRNAs 
were tested on CaSki or HeLa cell lines resulting in significant cell growth and colony 
formation inhibition in both cell lines with a significant increase in apoptosis. The siRNAs 
had no effect in HPV-negative C33-A cells, demonstrating a lack of off-target effects. In 
addition, a xenograft study showed that intratumor injection of the siRNAs reduced tumor 
growth in BALB/c nude mice (Chang et al., 2010). 
The transient nature of antisense technology (including siRNAs) forced research on long 
expression using vector-borne shRNAs. Although many reports have established the 
feasibility of this approach (Bai et al., 2006; Bousarghin et al., 2009; Gu et al., 2011), it is clear 
that prolonged siRNA expression may lead to dysfunction of the RNAi pathway (Tang et 
al., 2006) or other intracellular effects (Koivusalo et al., 2006) due to the sudden rise in p53 
and pRB proteins after siRNA treatment (Sima et al., 2008). Thus, siRNA treatment has been 
used to enhance already established therapies for cervical cancer such as paclitaxel (Liu et 
al., 2009), cisplatin (Wu et al., 2011) and TRAIL (Eaton et al., 2011) with sometimes mixed 
results depending on the condition of p53 expression (Koivusalo et al., 2005). 
As noted above, nucleotide modifications at specific positions enable oligonucleotides to 
avoid intracellular nuclease degradation and meddling with the endogenous RNAi 
pathway, but they also help to overcome off-targeting issues in siRNAs (Jackson et al., 2006). 
In addition, DNA inclusion in the seed region of the guide strand and its complementary 
sequence within the siRNA, so-called a double-stranded RNA–DNA chimera (dsRNA-
DNA), abolishes off-target effects sacrificing some silencing activity (Ui-Tei et al., 2008). 
Application of dsRNA-DNA chimeras from previously reported and highly active siRNAs 
to nt 497, 573 and 752 within HPV-16 E6/E7 mRNA (Yamato et al., 2008), resulted in 
reduced cytotoxicity in two of three chimeric siRNAs (497 and 752), but not in the other 
(573), correlating with their reported off-target effects. Silencing activity was marginally 
affected in chimeric siRNAs 497 and 573 and moderately in 752. Chimeric siRNA 497 
induced E6/E7-specific growth suppression of cervical cancer cells and E6/E7-immortalized 
human keratinocytes (Yamato et al., 2011). 
The delivery of antisense moieties has also attracted much attention in siRNA research. 
Unlike AS-ODNs, there is a stringent requirement for transfection of siRNAs that has 
limited its applications as powerful cell culture inhibitors. To become truly useful 
therapeutic moieties, in vivo delivery methods have been developed for cervical cancer 
treatment using siRNAs besides the obvious use of vector-borne shRNAs. These approaches 
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vary from the traditional direct intratumor injection (Fujii et al., 2006) to more innovative 
methods such as dendrosomal nanoparticles delivery (Dutta et al., 2010), encapsidation in 
HPV-16 virus-like particles (Bousarghin et al., 2005), encapsulation in lipidic particles (Wu et 
al., 2011) and coating of quantum dots (Zhao et al., 2011). All of these approaches showed 
the feasibility of in vivo siRNA treatment for cervical cancer. No clinical reports have been 
published so far. 
3.4.2 MicroRNAs (miRNAs) in cervical cancer 
The participation of miRNAs as regulatory molecules in differentiation, apoptosis, and 
proliferation strongly suggested a role in cervical cancer. Although miRNAs are not 
therapeutic or diagnostic oligonucleotides in strict sense, they can be used as synthetic 
moieties to block key biological processes leading to malignant transformation. Because the 
HPV life cycle is linked to epithelial differentiation and requires actively proliferating  
keratinocytes, it has been hypothesized that HPV proteins may modulate miRNA 
expression. Interestingly, high-risk HPVs do not encode for any known miRNA (Cai et al., 
2006; Lui et al., 2007), although they may control expression of cellular miRNAs to regulate 
the activities of cellular proteins through expression of viral regulatory proteins (i.e. E5, E7 
and E7) (Greco et al., 2011; Wang et al., 2009; Zheng & Wang, 2011). In the last few years, 
many alterations in cellular miRNA patterns in cervical cancer tissue or cervical cancer cells 
have been reported, suggesting that knowledge of differential miRNA expression may have 
a significant diagnostic and prognostic value (Lui et al., 2007). 
High-risk HPV E6 may exert modulation of miRNA expression through p53 down 
regulation. Cervical cancer cells containing high-risk HPVs show reduced expression of 
miR-34a, a p53 effector with tumor-suppressor abilities. Reduction of miR-34a expression in 
HPV-containing human keratinocytes correlated with expression of viral E6. Furthermore, 
siRNA knockdown of viral E6 expression in high-risk HPV-containing cervical cancer cell 
lines lead to increased expression of p53 and miR-34a and accumulation of miR-34a in 
G0/G1 phase cells. Ectopic expression of miR-34a in HPV-containing and HPV-negative 
cells resulted in substantial cell proliferation inhibition and moderate apoptosis, suggesting 
HPV modulation of cellular miRNA expression (Wang et al., 2009). The HPV-16 E6 was also 
found to decrease expression of miR-23b in SiHa and CaSki cells by repressing the promoter 
and increased expression of its cellular target, the urokinase-type plasminogen activator 
(uPA), a known inductor of cell migration in cervical cancer cells. The link between HPV-16 
E6 and miR-23b transcription was associated to the presence of a p53 binding site within the 
miR-23b promoter, suggesting a cell migration modulatory role for E6 (Au Yeung et al., 
2011). 
High-risk HPV E7 expression in human keratinocytes modulated expression of human miR-
203 and its downstream target, ΔNp63. Although the underlying mechanism is not fully 
understood, E7 is sufficient for blocking miR-203 expression probably by modulation of the 
mitogen-activated protein kinase (MAPK) pathway signaling. The p63 family, is related to 
the p53 tumor suppressor. ΔNp63 isoform is expressed at high levels in proliferating 
undifferentiated basal keratinocytes, and its expression is down-regulated in differentiated 
non-proliferating cells. Down-regulation of ΔNp63 has been associated to regulation of 
epithelial proliferation and differentiation. Thus, inhibition of miR-203 allows HPV 
productive replication in differentiating cells (Melar-New & Laimins, 2010). Interestingly, 
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expression of the high-risk HPV-16 E5 protein (considered an overall enhancer of E6/E7 
activities) resulted in rapid (96 hours) alteration of  miR-146a, miR-203 and miR-324-5p and 
their target genes in transfected keratinocytes, suggesting a miRNA regulatory role for E5 
(Greco et al., 2011). 
Genomic microarray analyses in normal and cervical cancer tissues using the same miRNA 
array platform showed increased expression miR-15b, miR-16, miR-17-5p, miR-20a, miR-
20b, miR-21, miR-93, miR-106a, miR-155, miR-182, miR-185, and miR-224 and decreased 
expression of miR-29a, miR-34a, miR-126, miR-127, miR-145, miR-218, miR-424, miR-450, 
and miR-455) in cervical cancer tissues (Li et al., 2010; Wang et al., 2008). Further 
confirmation of miR-126, miR-143/145, miR-155, and miR-424/450 alterations was 
performed by deep sequencing (Witten et al., 2010). Other studies with customized miRNA 
arrays and different assay platforms showed increased miR-21 expression in cervical cancer, 
a common occurrence in cancer cells (Lui et al., 2007). More interestingly, miR-143 and miR-
145 showed basically null expression in cancer samples, suggesting the potential value of 
these miRNAs as tumor markers (Lui et al., 2007; Pereira et al., 2010). Yet another study 
concluded that infection with high-risk HPV lowered miR-218 expression suggesting a role 
for miR-218 in the pathogenesis of cervical cancer. Nevertheless, the specific role of all these 
miRNAs in cervical carcinogenesis and HPV infection is unknown.  
The growth inhibitory activity of miR-34c-3p was recently shown by our group in SiHa cells 
but not in other cell types. Although the inhibitory mechanism is not clear, transfection of a 
mi34c-3p mimic resulted in specific fast apoptosis induction (24 hours), inhibition of colony 
formation, cell migration and invasion, suggesting a potential therapeutic use for this 
miRNA (Lopez & Alvarez-Salas, 2011).  
3.5 Aptamers 
Aptamers are single-stranded oligonucleotides that, unlike AS-ODNs and siRNAs, function 
by folding into specific globular structures that dictate high-affinity binding to a variety of 
targets (Cerchia et al., 2002). They are often referred as functional homologues of the 
antibodies and are obtained through the use of the systematic evolution of ligands by 
exponential enrichment (SELEX) procedure. The SELEX method is a PCR-based in vitro 
selection procedure of large oligonucleotide libraries that recapitulates natural evolution 
resulting in the isolation of specific ligands that bind with high affinity to a wide variety of 
proteins and cell surface epitopes (Ellington & Szostak, 1990; Tuerk & Gold, 1990). These 
molecules have been used in flow cytometry, biosensors, affinity probe electrophoresis, 
capillary electrochromatography, and affinity chromatography (Yan et al., 2005).  
Notwithstanding the obvious value of aptamer for diagnostics, the incorporation of 
modified nucleotides into RNA transcripts resulting in stability in biofluids has 
considerably increased the use of aptamers as probes to inhibit protein functions (Pagratis et 
al., 1997). Nuclease-resistant RNA and DNA aptamers to block cell adhesion events gained 
importance in the last years. Wang et al., selected RNA aptamers that bind to infectious 
human cytomegalovirus and inhibit viral infection in vitro, showing the feasibility of the 
SELEX technique for the evolution of novel compounds that protect cells against infection 
by pathogens such HPV (Wang et al., 2000). Furthermore, combinatorial synthesized 
nuclease-resistant RNA and DNA aptamers are promising candidates for use in diagnostic 
and therapeutic onsets.  
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3.5.1 Aptamers on HPV detection and therapy 
Even though oligonucleotide aptamer technologies have been available for a number of 
years, it is only beginning to be established for HPV detection. During its life cycle, HPV 
expresses proteins according the cellular differentiation program that is modified after E2 
disruption and the onset of malignant transformation (Pett & Coleman, 2007; Xue et al., 
2010). Such features offer several protein targets for the detection of HPV infection and 
molecular diagnosis of cervical cancer by using aptamers as diagnostic oligonucleotides. The 
first aptamer directed against high-risk HPV proteins was obtained using a modified SELEX 
in which unspecific sequences were eliminated applying an antidote-like strategy (Toscano-
Garibay et al., 2011). This RNA aptamer effectively recognized the viral protein in a purified 
form with affinity comparable to other aptamers that bind small proteins. In addition, the 
interacting mechanism was common to those observed for little targets; it folds into two 
hairpin structures and wraps E7 making contact with independent sites located on the CR1 
and CR3 protein domains. Even though its behavior with infected cell extracts showed a 
cross-recognition between at least two types of HPV, this aptamer constitutes an important 
step towards the design of reliable and affordable detection methods. 
A second set of aptamers obtained against E7 has established the effect of a single nucleotide 
changes on the function of aptamers over the protein activity. By changing only one 
nucleotide (U>C) anti-E7 aptamers prevented the formation of pRB-E7 complexes, 
meanwhile the replacement of two bases conducted to inactive sequences (Nicol et al., 2011). 
These observations suggest that following a mutation-by-mutation planning process or even 
using error prone PCR, some of the obtained aptamers could improve intracellular stability 
to impede the activity E7 proteins and eventually become a complement for therapies 
against cervical cancer.  
4. Conclusion 
Over the last few years, small oligonucleotides have been proved as feasible alternatives to 
HPV infection and cervical cancer therapy. The most common and successful approaches 
appoint to antisense technology in the form of siRNAs and AS-ODNs against different 
target sequences within high-risk HPV E6/E7 mRNA. Above all, siRNA technology shows a 
higher capacity than AS-ODNs to inhibit HPV expression. However, siRNA-induced 
inhibition of high-risk HPV E6/E7 is still far from practical use, limiting research to cell 
culture applications. Several issues regarding the transient nature of siRNA-mediated 
inhibition and the associated and always difficult to control off-target effects have 
undermined the clinical application of this otherwise powerful technology. The ability to 
efficiently and stably produce and deliver sufficient amounts of siRNA to the proper target 
tissues still requires further refinement although recent advancements in siRNA delivery 
(encapsulation) and the use of modified nucleotides in synthetic siRNAs may finally allow 
clinical testing for cervical cancer. The use of vectors-borne shRNAs appears as a more 
distant solution due to the multiple ethical and biological issues arising from the use of viral 
vectors and the still impractical non-viral approaches (i.e. liposomes, dendrosomes, 
quantum dots, etc.). 
Even though off-targeting and delivery issues might be overcome the intracellular presence 
of any antisense moiety or siRNA must confront the role of innate immune responses. AS-
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ODNs have been shown to induce distinct classes of innate responses that can mislead data 
interpretation by masking true antisense effects in the clinical setup. In particular, the 
presence of CpG dinucleotides along the AS-ODN sequence that activate the immune 
system through Toll-like receptor 9 (TLR9), resulting in cytokine release and antitumor 
cytotoxicity (Kandimalla et al., 2005; Sivori et al., 2004). Transfection of unmodified siRNAs 
and shRNAs trigger a similar response through TLR3 and TLR7 (Judge et al., 2005). In fact, a 
whole new class of oligonucleotides known as IM-ONs that is virtually unexplored in the 
HPV and cervical cancer setup as therapeutical moieties or vaccine adjuvants.  
The involvement of miRNAs in cervical carcinogenesis has opened a new dimension in HPV 
research. Although many reports establish the alteration of a myriad of miRNAs, it is 
becoming clear that most of these are artifacts. A more stringent protocol should be used to 
establish participation of miRNAs in cervical cancer including functional assays in HPV-
positive and HPV-negative cervical cells and in situ detection in normal and tumor cervical 
tissues. Nevertheless, HPV modulation of miRNA expression is firmly established. The use 
of aptamers in cervical cancer diagnosis and HPV detection is promising as the natural 
history of HPV infection offers a plethora of targets previously addressed with antibodies. 
As SELEX-derived oligonucleotides grow in diversity and specificity, new and cost-effective 
aptamer-based technologies will provide fast and reliable prevention and early screening 
strategies that will compete with massive vaccination programs in the future. No use of 
aptamers in cervical cancer therapy has been reported, but the use of AS-ODNs and 
aptamers currently accepted by the FDA and the advent of new RNA therapeutic targets 
(i.e. miRNAs), suggest that the best options for the clinical application of oligonucleotides 
against cervical cancer are yet to come. 
5. Acknowledgement 
This work was partially supported by ICYTDF grant 313/2009 to LMAS. 
6. References 
Agrawal, S.; Mayrand, S. H.; Zamecnik, P. C. & Pederson, T. (1990). Site-specific excision 
from RNA by RNase H and mixed-phosphate- backbone oligodeoxynucleotides. 
Proc.Natl.Acad.Sci.U.S.A., Vol.87, pp. 1401-1405 
Agrawal, S. & Zhang, R. (1997). Pharmacokinetics of oligonucleotides. Ciba.Found.Symp., 
Vol.209, pp. 60-75 
Agrawal, S. & Zhao, Q. (1998). Mixed backbone oligonucleotides: improvement in 
oligonucleotide-induced toxicity in vivo. Antisense.Nucleic.Acid.Drug Dev., Vol.8, 
pp. 135-139 
Akhtar, S. & Agrawal, S. (1997). In vivo studies with antisense oligonucleotides. 
Trends.Pharmacol.Sci., Vol.18, pp. 12-18 
Ali, M.M.; Aguirre, S. D.; Lazim, H. & Li, Y. (2011). Fluorogenic DNAzyme probes as 
bacterial indicators. Angew.Chem.Int.Ed Engl., Vol.50, pp. 3751-3754 
Alvarez-Salas, L.M. (2008). Nucleic acids as therapeutic agents. Curr.Top.Med.Chem., Vol.8, 
pp. 1379-1404 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 112 
Alvarez-Salas, L.M.; Arpawong, T. E. & DiPaolo, J. A. (1999). Growth inhibition of cervical 
tumor cells by antisense oligodeoxynucleotides directed to the human 
papillomavirus type 16 E6 gene. Antisense.Nucleic.Acid.Drug Dev., Vol.9, pp. 441-450 
Alvarez-Salas, L.M.; Cullinan, A. E.; Siwkowski, A.; Hampel, A. & DiPaolo, J. A. (1998). 
Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin 
ribozymes. Proc.Natl.Acad.Sci.U.S.A., Vol.95, pp. 1189-1194 
Alvarez-Salas, L.M. & DiPaolo, J. A. (2007). Molecular approaches to cervical cancer therapy. 
Curr.Drug Discov.Technol., Vol.4, pp. 208-219 
Alvarez-Salas, L.M.; Wilczynski, S. P.; Burger, R. A.; Monk, B. J. & DiPaolo, J. A. (1995). 
Polymorphism of the HPV-16 E6 gene of cervical carcinoma. Int.J.Oncol., Vol.7, pp. 
261-266 
Anderson, P.; Monforte, J.; Tritz, R.; Nesbitt, S.; Hearst, J. & Hampel, A. (1994). Mutagenesis 
of the hairpin ribozyme. Nucleic.Acids Res., Vol.22, pp. 1096-1100 
Aquino-Jarquin, G.; Benitez-Hess, M. L.; DiPaolo, J. A. & Alvarez-Salas, L. M. (2008). A 
Triplex Ribozyme Expression System Based on a Single Hairpin Ribozyme. 
Oligonucleotides., Vol.18, pp. 213-224 
Aquino-Jarquin, G.; Rojas-Hernandez, R. & Alvarez-Salas, L. M. (2010). Design and function 
of triplex hairpin ribozymes. Methods Mol.Biol., Vol.629, pp. 323-338 
Arbyn, M.; Castellsague, X.; de, S. S.; Bruni, L.; Saraiya, M.; Bray, F. & Ferlay, J. (2011). 
Worldwide burden of cervical cancer in 2008. Ann.Oncol., Vol.doi: 
10.1093/annonc/mdr015, pp.  
Au Yeung, C.L.; Tsang, T. Y.; Yau, P. L. & Kwok, T. T. (2011). Human papillomavirus type 
16 E6 induces cervical cancer cell migration through the p53/microRNA-
23b/urokinase-type plasminogen activator pathway. Oncogene., Vol.30, pp. 2401-
2410 
Bai, L.; Wei, L.; Wang, J.; Li, X. & He, P. (2006). Extended effects of human papillomavirus 16 
E6-specific short hairpin RNA on cervical carcinoma cells. Int.J.Gynecol.Cancer., 
Vol.16, pp. 718-729 
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell., 
Vol.116, pp. 281-297 
Baum, D.A. & Silverman, S. K. (2008). Deoxyribozymes: useful DNA catalysts in vitro and in 
vivo. Cell Mol.Life Sci., Vol.65, pp. 2156-2174 
Benitez-Hess, M.L. & Alvarez-Salas, L. M. (2006). Utilization of ribozymes as antiviral 
agents. Letters Drug Design & Discovery., Vol.3, pp. 390-404 
Benitez-Hess, M.L.; Reyes-Gutierrez, P. & Alvarez-Salas, L. M. (2011). Inhibition of Human 
Papillomavirus Expression Using DNAzymes. Methods Mol.Biol., Vol.764:317-35., 
pp. 317-335 
Berezikov, E.; Chung, W. J.; Willis, J.; Cuppen, E. & Lai, E. C. (2007). Mammalian mirtron 
genes. Mol.Cell., Vol.28, pp. 328-336 
Berezutskaya, E.; Yu, B.; Morozov, A.; Raychaudhuri, P. & Bagchi, S. (1997). Differential 
regulation of the pocket domains of the retinoblastoma family proteins by the 
HPV16 E7 oncoprotein. Cell Growth Differ., Vol.8, pp. 1277-1286 
Bernstein, E.; Caudy, A. A.; Hammond, S. M. & Hannon, G. J. (2001). Role for a bidentate 
ribonuclease in the initiation step of RNA interference. Nature., Vol.409, pp. 363-366 
Bonham, M.A.; Brown, S.; Boyd, A. L.; Brown, P. H.; Bruckenstein, D. A.; Hanvey, J. C.; 
Thomson, S. A.; Pipe, A.; Hassman, F. & Bisi, J. E. (1995). An assessment of the 
www.intechopen.com
 
Oligonucleotide Applications for the Therapy and Diagnosis of Human Papillomavirus Infection 113 
antisense properties of RNase H-competent and steric-blocking oligomers. 
Nucleic.Acids Res., Vol.23, pp. 1197-1203 
Bousarghin, L.; Hubert, P.; Franzen, E.; Jacobs, N.; Boniver, J. & Delvenne, P. (2005). Human 
papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells 
and colocalize with langerin in Langerhans cells. J.Gen.Virol., Vol.86, pp. 1297-1305 
Bousarghin, L.; Touze, A.; Gaud, G.; Iochmann, S.; Alvarez, E.; Reverdiau, P.; Gaitan, J.; 
Jourdan, M. L.; Sizaret, P. Y. & Coursaget, P. L. (2009). Inhibition of cervical cancer 
cell growth by human papillomavirus virus-like particles packaged with human 
papillomavirus oncoprotein short hairpin RNAs. Mol.Cancer Ther., Vol.8, pp. 357-
365 
Boyer, S.N.; Wazer, D. E. & Band, V. (1996). E7 protein of human papilloma virus-16 induces 
degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. 
Cancer Res., Vol.56, pp. 4620-4624 
Butz, K.; Denk, C.; Ullmann, A.; Scheffner, M. & Hoppe-Seyler, F. (2000). Induction of 
apoptosis in human papillomaviruspositive cancer cells by peptide aptamers 
targeting the viral E6 oncoprotein. Proc.Natl.Acad.Sci.U.S.A., Vol.97, pp. 6693-6697 
Butz, K.; Ristriani, T.; Hengstermann, A.; Denk, C.; Scheffner, M. & Hoppe-Seyler, F. (2003). 
siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-
positive cancer cells. Oncogene., Vol.22, pp. 5938-5945 
Cai, X.; Li, G.; Laimins, L. A. & Cullen, B. R. (2006). Human papillomavirus genotype 31 
does not express detectable microRNA levels during latent or productive virus 
replication. J.Virol., Vol.80, pp. 10890-10893 
Cairns, M.J.; King, A. & Sun, L. Q. (2003). Optimisation of the 10-23 DNAzyme-substrate 
pairing interactions enhanced RNA cleavage activity at purine-cytosine target sites. 
Nucleic.Acids.Res., Vol.31, pp. 2883-2889 
Carbone, G.M.; McGuffie, E. M.; Collier, A. & Catapano, C. V. (2003). Selective inhibition of 
transcription of the Ets2 gene in prostate cancer cells by a triplex-forming 
oligonucleotide. Nucleic.Acids.Res., Vol.31, pp. 833-843 
Cerchia, L.; Hamm, J.; Libri, D.; Tavitian, B. & de, F., V (2002). Nucleic acid aptamers in 
cancer medicine. FEBS Lett., Vol.528, pp. 12-16 
Chang, J.T.; Kuo, T. F.; Chen, Y. J.; Chiu, C. C.; Lu, Y. C.; Li, H. F.; Shen, C. R. & Cheng, A. J. 
(2010). Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or 
HPV18-infected cervical cancers. Cancer Gene Ther., Vol.17, pp. 827-836 
Chen, Z.; Kamath, P.; Zhang, S.; St.John, L.; Adler-Storthz, K. & Shillitoe, E. J. (1996). Effects 
on tumor cells of ribozymes that cleave the RNA transcripts of human 
papillomavirus type 18. Cancer Gene Ther., Vol.3, pp. 18-23 
Chen, Z.; Kamath, P.; Zhang, S.; Weil, M. M. & Shillitoe, E. J. (1995). Effectiveness of three 
ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. 
Cancer Gene Ther., Vol.2, pp. 263-271 
Cherny, D.I.; Malkov, V. A.; Volodin, A. A. & Frank-Kamenetskii, M. D. (1993). Electron 
microscopy visualization of oligonucleotide binding to duplex DNA via triplex 
formation. J.Mol.Biol., Vol.230, pp. 379-383 
Cho, C.W.; Poo, H.; Cho, Y. S.; Cho, M. C.; Lee, K. A.; Lee, S. J.; Park, S. N.; Kim, I. K.; Jung, 
Y. K.; Choe, Y. K.; Yeom, Y. I.; Choe, I. S. & Yoon, d. Y. (2002). HPV E6 antisense 
induces apoptosis in CaSki cells via suppression of E6 splicing. Exp.Mol.Med., 
Vol.34, pp. 159-166 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 114 
Choo, C.K.; Ling, M. T.; Suen, C. K.; Chan, K. W. & Kwong, Y. L. (2000). Retrovirus-
mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki 
cells. Gynecol.Oncol., Vol.78, pp. 293-301 
Clifford, G.M.; Smith, J. S.; Plummer, M.; Munoz, N. & Franceschi, S. (2003). Human 
papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. 
Br.J.Cancer., Vol.88, pp. 63-73 
Crooke, S.T. (1999). Molecular mechanisms of action of antisense drugs. 
Biochim.Biophys.Acta., Vol.1489, pp. 31-44 
Cullen, B.R. (2004). Transcription and processing of human microRNA precursors. Mol.Cell., 
Vol.16, pp. 861-865 
Cullen, B.R. (2006). Induction of stable RNA interference in mammalian cells. Gene Ther., 
Vol.13, pp. 503-508 
Dass, C.R.; Choong, P. F. & Khachigian, L. M. (2008). DNAzyme technology and cancer 
therapy: cleave and let die. Mol.Cancer Ther., Vol.7, pp. 243-251 
Du, L. & Gatti, R. A. (2009). Progress toward therapy with antisense-mediated splicing 
modulation. Curr.Opin.Mol.Ther., Vol.11, pp. 116-123 
Duensing, S.; Duensing, A.; Flores, E. R.; Do, A.; Lambert, P. F. & Munger, K. (2001). 
Centrosome abnormalities and genomic instability by episomal expression of 
human papillomavirus type 16 in raft cultures of human keratinocytes. J.Virol., 
Vol.75, pp. 7712-7716 
Duensing, S.; Lee, L. Y.; Duensing, A.; Basile, J.; Piboonniyom, S.; Gonzalez, S.; Crum, C. P. 
& Munger, K. (2000). The human papillomavirus type 16 E6 and E7 oncoproteins 
cooperate to induce mitotic defects and genomic instability by uncoupling 
centrosome duplication from the cell division cycle. Proc.Natl.Acad.Sci.U.S.A., 
Vol.97, pp. 10002-10007 
Dutta, T.; Burgess, M.; McMillan, N. A. & Parekh, H. S. (2010). Dendrosome-based delivery 
of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine., Vol.6, pp. 
463-470 
Eaton, S.; Wiktor, P.; Thirstrup, D.; Lake, D. & Nagaraj, V. J. (2011). Efficacy of TRAIL 
treatment against HPV16 infected cervical cancer cells undergoing senescence 
following siRNA knockdown of E6/E7 genes. Biochem.Biophys.Res.Commun., 
Vol.405, pp. 1-6 
Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K. & Tuschl, T. (2001). 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature., Vol.411, pp. 494-498 
Ellington, A.D. & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific 
ligands. Nature., Vol.346, pp. 818-822 
Epstein, L.M. & Gall, J. G. (1987). Transcripts of newt satellite DNA self-cleave in vitro. Cold 
Spring Harb.Symp.Quant.Biol., Vol.52:261-5., pp. 261-265 
Etscheid, B.G.; Foster, S. A. & Galloway, D. A. (1994). The E6 protein of human 
papillomavirus type 16 functions as a transcriptional repressor in a mechanism 
independent of the tumor suppressor protein, p53. Virology, Vol.205, pp. 583-585 
Faulhammer, D. & Famulok, M. (1997). Characterization and divalent metal-ion dependence 
of in vitro selected deoxyribozymes which cleave DNA/RNA chimeric 
oligonucleotides. J.Mol.Biol., Vol.269, pp. 188-202 
www.intechopen.com
 
Oligonucleotide Applications for the Therapy and Diagnosis of Human Papillomavirus Infection 115 
Filippova, M.; Song, H.; Connolly, J. L.; Dermody, T. S. & Duerksen-Hughes, P. J. (2002). The 
human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and 
protects cells from TNF-induced apoptosis. J.Biol.Chem., Vol.277, pp. 21730-21739 
Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E. & Mello, C. C. (1998). Potent 
and specific genetic interference by double-stranded RNA in Caenorhabditis 
elegans. Nature., Vol.391, pp. 806-811 
Fujii, T.; Saito, M.; Iwasaki, E.; Ochiya, T.; Takei, Y.; Hayashi, S.; Ono, A.; Hirao, N.; 
Nakamura, M.; Kubushiro, K.; Tsukazaki, K. & Aoki, D. (2006). Intratumor injection 
of small interfering RNA-targeting human papillomavirus 18 E6 and E7 
successfully inhibits the growth of cervical cancer. Int.J.Oncol., Vol.29, pp. 541-548 
Funk, J.O.; Waga, S.; Harry, J. B.; Espling, E.; Stillman, B. & Galloway, D. A. (1997). 
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is 
blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev., Vol.11, pp. 
2090-2100 
Gardiol, D.; Kuhne, C.; Glaunsinger, B.; Lee, S. S.; Javier, R. & Banks, L. (1999). Oncogenic 
human papillomavirus E6 proteins target the discs large tumour suppressor for 
proteasome-mediated degradation. Oncogene, Vol.18, pp. 5487-5496 
Gewin, L.; Myers, H.; Kiyono, T. & Galloway, D. A. (2004). Identification of a novel 
telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-
AP complex. Genes Dev., Vol.18, pp. 2269-2282 
Glaunsinger, B.A.; Lee, S. S.; Thomas, M.; Banks, L. & Javier, R. (2000). Interactions of the 
PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 
oncoproteins. Oncogene, Vol.19, pp. 5270-5280 
Greco, D.; Kivi, N.; Qian, K.; Leivonen, S. K.; Auvinen, P. & Auvinen, E. (2011). Human 
Papillomavirus 16 E5 Modulates the Expression of Host MicroRNAs. PLoS.ONE., 
Vol.6, pp. e21646- 
Gregory, R.I. & Shiekhattar, R. (2005). MicroRNA biogenesis and cancer. Cancer Res., Vol.65, 
pp. 3509-3512 
Gu, W.; Payne, E.; Sun, S.; Burgess, M. & McMillan, N. A. (2011). Inhibition of cervical 
cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Ther., Vol.18, 
pp. 219-227 
Guerrier-Takada, C.; Gardiner, K.; Marsh, T.; Pace, N. & Altman, S. (1983). The RNA moiety 
of ribonuclease P is the catalytic subunit of the enzyme. Cell, Vol.35, pp. 849-857 
Hall, A.H. & Alexander, K. A. (2003). RNA Interference of Human Papillomavirus Type 18 
E6 and E7 Induces Senescence in HeLa Cells. J.Virol., Vol.77, pp. 6066-6069 
Hammond, S.M.; Caudy, A. A. & Hannon, G. J. (2001). Post-transcriptional gene silencing by 
double-stranded RNA. Nat.Rev.Genet., Vol.2, pp. 110-119 
Hampel, A.; Tritz, R.; Hicks, M. & Cruz, P. (1990). 'Hairpin' catalytic RNA model: evidence 
for helices and sequence requirement for substrate RNA. Nucleic.Acids Res., Vol.18, 
pp. 299-304 
Hartman, D.A.; Kuo, S. R.; Broker, T. R.; Chow, L. T. & Wells, R. D. (1992). Intermolecular 
triplex formation distorts the DNA duplex in the regulatory region of human 
papillomavirus type-11. J.Biol.Chem., Vol.267, pp. 5488-5494 
Haseloff, J. & Gerlach, W. L. (1988). Simple RNA enzymes with new and highly specific 
endoribonuclease activities. Nature., Vol.334, pp. 585-591 
Haseloff, J. & Gerlach, W. L. (1989). Sequences required for self-catalysed cleavage of the 
satellite RNA of tobacco ringspot virus. Gene., Vol.82, pp. 43-52 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 116 
Hayashi, S.; Nagasaka, T.; Katayama, A.; Saito, I.; Hamada, H.; Kobayashi, T.; Yokoyama, I.; 
Ohtsuka, S.; Uchida, K. & Takagi, H. (1997). Adenovirus-mediated gene transfer of 
antisense ribozyme for alpha (1,3)galactosyltransferase gene and alpha (1, 
2)fucosyltransferase gene in xenotransplantation. Transplant.Proc., Vol.29, pp. 2213-
2213 
He, Y.K.; Lu, C. D. & Qi, G. R. (1993). In vitro cleavage of HPV16 E6 and E7 RNA fragments 
by synthetic ribozymes and transcribed ribozymes from RNA-trimming plasmids. 
FEBS Lett., Vol.322, pp. 21-24 
Hebner, C.M. & Laimins, L. A. (2006). Human papillomaviruses: basic mechanisms of 
pathogenesis and oncogenicity. Rev.Med.Virol., Vol.16, pp. 83-97 
Howie, H.L.; Katzenellenbogen, R. A. & Galloway, D. A. (2009). Papillomavirus E6 proteins. 
Virology., Vol.384, pp. 324-334 
Huh, K.W.; DeMasi, J.; Ogawa, H.; Nakatani, Y.; Howley, P. M. & Munger, K. (2005). 
Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa 
retinoblastoma protein-associated factor, p600. Proc.Natl.Acad.Sci.U.S.A., Vol.102, 
pp. 11492-11497 
Huibregtse, J.M.; Scheffner, M. & Howley, P. M. (1991). A cellular protein mediates 
association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. 
EMBO J., Vol.10, pp. 4129-4135 
Hutchins, C.J.; Rathjen, P. D.; Forster, A. C. & Symons, R. H. (1986). Self-cleavage of plus 
and minus RNA transcripts of avocado sunblotch viroid. Nucleic.Acids Res., Vol.14, 
pp. 3627-3640 
Hwang, S.G.; Lee, D.; Kim, J.; Seo, T. & Choe, J. (2002). Human papillomavirus type 16 E7 
binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-
independent manner. J.Biol.Chem., Vol.277, pp. 2923-2930 
Jackson, A.L.; Bartz, S. R.; Schelter, J.; Kobayashi, S. V.; Burchard, J.; Mao, M.; Li, B.; Cavet, 
G. & Linsley, P. S. (2003). Expression profiling reveals off-target gene regulation by 
RNAi. Nat.Biotechnol., Vol.21, pp. 635-637 
Jackson, A.L.; Burchard, J.; Leake, D.; Reynolds, A.; Schelter, J.; Guo, J.; Johnson, J. M.; Lim, 
L.; Karpilow, J.; Nichols, K.; Marshall, W.; Khvorova, A. & Linsley, P. S. (2006). 
Position-specific chemical modification of siRNAs reduces "off-target" transcript 
silencing. RNA., Vol.12, pp. 1197-1205 
Jiang, M. & Milner, J. (2002). Selective silencing of viral gene expression in HPV-positive 
human cervical carcinoma cells treated with siRNA, a primer of RNA interference. 
Oncogene, Vol.21, pp. 6041-6048 
Jones, D.L.; Alani, R. M. & Munger, K. (1997). The human papillomavirus E7 oncoprotein 
can uncouple cellular differentiation and proliferation in human keratinocytes by 
abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev., Vol.11, pp. 2101-2111 
Jonson, A.L.; Rogers, L. M.; Ramakrishnan, S. & Downs, L. S., Jr. (2008). Gene silencing with 
siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical 
cancer. Gynecol.Oncol., Vol.111, pp. 356-364 
Judge, A.D.; Sood, V.; Shaw, J. R.; Fang, D.; McClintock, K. & MacLachlan, I. (2005). 
Sequence-dependent stimulation of the mammalian innate immune response by 
synthetic siRNA. Nat.Biotechnol., Vol.23, pp. 457-462 
Kalali, B.N.; Kollisch, G.; Mages, J.; Muller, T.; Bauer, S.; Wagner, H.; Ring, J.; Lang, R.; 
Mempel, M. & Ollert, M. (2008). Double-stranded RNA induces an antiviral defense 
www.intechopen.com
 
Oligonucleotide Applications for the Therapy and Diagnosis of Human Papillomavirus Infection 117 
status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-
mediated differential signaling. J.Immunol., Vol.181, pp. 2694-2704 
Kandimalla, E.R.; Bhagat, L.; Li, Y.; Yu, D.; Wang, D.; Cong, Y. P.; Song, S. S.; Tang, J. X.; 
Sullivan, T. & Agrawal, S. (2005). Immunomodulatory oligonucleotides containing 
a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 
agonists. Proc.Natl.Acad.Sci.U.S.A., Vol.102, pp. 6925-6930 
Kari, I.; Syrjanen, S.; Johansson, B.; Peri, P.; He, B.; Roizman, B. & Hukkanen, V. (2007). 
Antisense RNA directed to the human papillomavirus type 16 E7 mRNA from 
herpes simplex virus type 1 derived vectors is expressed in CaSki cells and 
downregulates E7 mRNA. Virol.J., Vol.4, pp. 47-58 
Kim, Y.K. & Kim, V. N. (2007). Processing of intronic microRNAs. EMBO J., Vol.26, pp. 775-
783 
Klingelhutz, A.J.; Foster, S. A. & McDougall, J. K. (1996). Telomerase activation by the E6 
gene product of human papillomavirus type 16. Nature., Vol.380, pp. 79-82 
Koivusalo, R.; Krausz, E.; Helenius, H. & Hietanen, S. (2005). Chemotherapy compounds in 
cervical cancer cells primed by reconstitution of p53 function after short interfering 
RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect 
of siRNA in combination with different drugs. Mol.Pharmacol., Vol.68, pp. 372-382 
Koivusalo, R.; Mialon, A.; Pitkanen, H.; Westermarck, J. & Hietanen, S. (2006). Activation of 
p53 in cervical cancer cells by human papillomavirus E6 RNA interference is 
transient, but can be sustained by inhibiting endogenous nuclear export-dependent 
p53 antagonists. Cancer Res., Vol.66, pp. 11817-11824 
Kronenwett, R. & Sczakiel, G. (1997). Selection of fast-hybridizing complementary RNA 
species in vitro. Methods Mol.Biol., Vol.74, pp. 281-288 
Kruger, K.; Grabowski, P. J.; Zaug, A. J.; Sands, J.; Gottschling, D. E. & Cech, T. R. (1982). 
Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA 
intervining sequence of Tetrahymena. Cell, Vol.31, pp. 147-157 
Lea, J.S.; Sunaga, N.; Sato, M.; Kalahasti, G.; Miller, D. S.; Minna, J. D. & Muller, C. Y. (2007). 
Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition 
of cervical cancer cells. Reprod.Sci., Vol.14, pp. 20-28 
Lee, S.S.; Glaunsinger, B.; Mantovani, F.; Banks, L. & Javier, R. T. (2000). Multi-PDZ domain 
protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk 
papillomavirus type 18 E6 oncoproteins. J.Virol., Vol.74, pp. 9680-9693 
Lee, Y.; Kim, M.; Han, J.; Yeom, K. H.; Lee, S.; Baek, S. H. & Kim, V. N. (2004). MicroRNA 
genes are transcribed by RNA polymerase II. EMBO J., Vol.23, pp. 4051-4060 
Letai, A.G.; Palladino, M. A.; Fromm, E.; Rizzo, V. & Fresco, J. R. (1988). Specificity in 
formation of triple-stranded nucleic acid helical complexes: studies with agarose-
linked polyribonucleotide affinity columns. Biochemistry., Vol.27, pp. 9108-9112 
Li, B.; Hu, Y.; Ye, F.; Li, Y.; Lv, W. & Xie, X. (2010). Reduced miR-34a expression in normal 
cervical tissues and cervical lesions with high-risk human papillomavirus infection. 
Int.J.Gynecol.Cancer., Vol.20, pp. 597-604 
Lin, X.; Ruan, X.; Anderson, M. G.; McDowell, J. A.; Kroeger, P. E.; Fesik, S. W. & Shen, Y. 
(2005). siRNA-mediated off-target gene silencing triggered by a 7 nt 
complementation. Nucleic.Acids.Res., Vol.33, pp. 4527-4535 
Liu, W.L.; Green, N.; Seymour, L. W. & Stevenson, M. (2009). Paclitaxel combined with 
siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. 
Cancer Gene Ther., Vol.16, pp. 764-775 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 118 
Lopez, J.A. & Alvarez-Salas, L. M. (2011). Differential effects of miR-34c-3p and miR-34c-5p 
on SiHa cells proliferation apoptosis, migration and invasion. 
Biochem.Biophys.Res.Commun., Vol.409, pp. 513-519 
Lorenz, C.; Hadwiger, P.; John, M.; Vornlocher, H. P. & Unverzagt, C. (2004). Steroid and 
lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver 
cells. Bioorg.Med.Chem.Lett., Vol.14, pp. 4975-4977 
Lu, D.; Chatterjee, S.; Brar, D. & Wong, K. K., Jr. (1994). Ribozyme-mediated in vitro 
cleavage of transcripts arising from the major transforming genes of human 
papillomavirus type 16. Cancer Gene Ther., Vol.1, pp. 267-277 
Lui, W.O.; Pourmand, N.; Patterson, B. K. & Fire, A. (2007). Patterns of known and novel 
small RNAs in human cervical cancer. Cancer Res., Vol.67, pp. 6031-6043 
Malkov, V.A.; Voloshin, O. N.; Soyfer, V. N. & Frank-Kamenetskii, M. D. (1993). Cation and 
sequence effects on stability of intermolecular pyrimidine-purine-purine triplex. 
Nucleic.Acids.Res., Vol.21, pp. 585-591 
Marquez-Gutierrez, M.A.; Benitez-Hess, M. L.; DiPaolo, J. A. & Alvarez-Salas, L. M. (2007). 
Effect of combined antisense oligodeoxynucleotides directed against the human 
papillomavirus type 16 on cervical carcinoma cells. Arch.Med.Res., Vol.38, pp. 730-
738 
McLaughlin-Drubin, M.E.; Crum, C. P. & Munger, K. (2011). Human papillomavirus E7 
oncoprotein induces KDM6A and KDM6B histone demethylase expression and 
causes epigenetic reprogramming. Proc.Natl.Acad.Sci.U.S.A., Vol.108, pp. 2130-2135 
McLaughlin-Drubin, M.E.; Huh, K. W. & Munger, K. (2008). Human papillomavirus type 16 
E7 oncoprotein associates with E2F6. J.Virol., Vol.82, pp. 8695-8705 
McLaughlin-Drubin, M.E. & Munger, K. (2009). The human papillomavirus E7 oncoprotein. 
Virology., Vol.384, pp. 335-344 
Meister, G.; Landthaler, M.; Dorsett, Y. & Tuschl, T. (2004). Sequence-specific inhibition of 
microRNA- and siRNA-induced RNA silencing. RNA., Vol.10, pp. 544-550 
Melar-New, M. & Laimins, L. A. (2010). Human papillomaviruses modulate expression of 
microRNA 203 upon epithelial differentiation to control levels of p63 proteins. 
J.Virol., Vol.84, pp. 5212-5221 
Mercatante, D. & Kole, R. (2000). Modification of alternative splicing pathways as a potential 
approach to chemotherapy. Pharmacol.Ther., Vol.85, pp. 237-243 
Michienzi, A. & Rossi, J. J. (2001). Intracellular applications of ribozymes. Methods Enzymol., 
Vol.341, pp. 581-596 
Min, W.; Wen-Li, M.; Zhao-Hui, S.; Ling, L.; Bao, Z. & Wen-Ling, Z. (2009). Microarray 
analysis identifies differentially expressed genes induced by human 
papillomavirus type 18 E6 silencing RNA. Int.J.Gynecol.Cancer., Vol.19, pp. 547-563 
Miyagishi, M.; Hayashi, M. & Taira, K. (2003). Comparison of the suppressive effects of 
antisense oligonucleotides and siRNAs directed against the same targets in 
mammalian cells. Antisense.Nucleic.Acid.Drug Dev., Vol.13, pp. 1-7 
Moody, C.A. & Laimins, L. A. (2010). Human papillomavirus oncoproteins: pathways to 
transformation. Nat.Rev.Cancer., Vol.10, pp. 550-560 
Morrissey, D.V.; Lee, P. A.; Johnson, D. A.; Overly, S. L.; McSwiggen, J. A.; Beigelman, L.; 
Mokler, V. R.; Maloney, L.; Vargeese, C.; Bowman, K.; O'Brien, J. T.; Shaffer, C. S.; 
Conrad, A.; Schmid, P.; Morrey, J. D.; Macejak, D. G.; Pavco, P. A. & Blatt, L. M. 
(2002). Characterization of nuclease-resistant ribozymes directed against hepatitis B 
virus RNA. J.Viral.Hepat., Vol.9, pp. 411-418 
www.intechopen.com
 
Oligonucleotide Applications for the Therapy and Diagnosis of Human Papillomavirus Infection 119 
Moser, H.E. & Dervan, P. B. (1987). Sequence-specific cleavage of double helical DNA by 
triple helix formation. Science, Vol.238, pp. 645-650 
Munger, K. & Phelps, W. C. (1993). The human papillomavirus E7 protein as a transforming 
and transactivating factor. Biochim.Biophys.Acta., Vol.1155, pp. 111-123 
Nicol, C.; Bunka, D. H.; Blair, G. E. & Stonehouse, N. J. (2011). Effects of single nucleotide 
changes on the binding and activity of RNA aptamers to human papillomavirus 16 
E7 oncoprotein. Biochem.Biophys.Res.Commun., Vol.405, pp. 417-421 
Nykanen, A.; Haley, B. & Zamore, P. D. (2001). ATP requirements and small interfering 
RNA structure in the RNA interference pathway. Cell, Vol.107, pp. 309-321 
Oh, S.T.; Kyo, S. & Laimins, L. A. (2001). Telomerase activation by human papillomavirus 
type 16 E6 protein: induction of human telomerase reverse transcriptase expression 
through Myc and GC-rich Sp1 binding sites. J.Virol., Vol.75, pp. 5559-5566 
Pagratis, N.C.; Bell, C.; Chang, Y. F.; Jennings, S.; Fitzwater, T.; Jellinek, D. & Dang, C. 
(1997). Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of 
keratinocyte growth factor. Nat.Biotechnol., Vol.15, pp. 68-73 
Patil, S.D.; Rhodes, D. G. & Burgess, D. J. (2005). DNA-based therapeutics and DNA delivery 
systems: a comprehensive review. AAPS.J., Vol.7, pp. E61-E77 
Pereira, P.M.; Marques, J. P.; Soares, A. R.; Carreto, L. & Santos, M. A. (2010). MicroRNA 
Expression Variability in Human Cervical Tissues. PLoS.ONE., Vol.5, pp. e11780- 
Pett, M. & Coleman, N. (2007). Integration of high-risk human papillomavirus: a key event 
in cervical carcinogenesis? J.Pathol., Vol.212, pp. 356-367 
Pirisi, L.; Creek, K. E.; Doniger, J. & DiPaolo, J. A. (1988). Continuous cell lines with altered 
growth and differentiation properties originate after transfection of human 
keratinocytes with human papillomavirus type 16 DNA. Carcinogenesis., Vol.9, pp. 
1573-1579 
Popa, L.M.; Schutz, H.; Winter, S.; Kittler, L. & Lober, G. (1996). Specific targeting of human 
papillomavirus type 16 E7 oncogene with triple-helix forming purine 
oligodeoxyribonucleotides. Biochem.Mol.Biol.Int., Vol.38, pp. 285-295 
Prody, G.A.; Bakos, J. T.; Buzayan, J. M.; Schneider, I. R. & Bruening, G. (1986). Autolytic 
processing of dimeric plant virus satellite RNA. Science, Vol.321, pp. 1577-1580 
Qi, Z.; Xu, X.; Zhang, B.; Li, Y.; Liu, J.; Chen, S.; Chen, G. & Huo, X. (2010). Effect of 
simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis in HeLa cells. 
Biochem.Cell Biol., Vol.88, pp. 697-704 
Reyes-Gutierrez, P. & Alvarez-Salas, L. M. (2009). Cleavage of HPV-16 E6/E7 mRNA 
mediated by modified 10-23 deoxyribozymes. Oligonucleotides., Vol.19, pp. 233-242 
Santoro, S.W. & Joyce, G. F. (1997). A general purpose RNA-cleaving DNA enzyme. 
Proc.Natl.Acad.Sci.U.S.A., Vol.94, pp. 4262-4266 
Santoro, S.W. & Joyce, G. F. (1998). Mechanism and utility of an RNA-cleaving DNA 
enzyme. Biochemistry., Vol.37, pp. 13330-13342 
Scheffner, M.; Huibregtse, J. M.; Vierstra, R. D. & Howley, P. M. (1993). The HPV-16 E6 and 
E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. 
Cell., Vol.75, pp. 495-505 
Schneider-Gadicke, A. & Schwarz, E. (1986). Different human cervical carcinoma cell lines 
show similar transcription patterns of human papillomavirus type 18 early genes. 
EMBO J., Vol.5, pp. 2285-2292 
Sharp, P.A. (1999). RNAi and double-strand RNA. Genes Dev., Vol.13, pp. 139-141 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 120 
Shillitoe, E.J. (2006). Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther., 
Vol.13, pp. 445-450 
Shim, M.S. & Kwon, Y. J. (2010). Efficient and targeted delivery of siRNA in vivo. FEBS J., 
Vol.277, pp. 4814-4827 
Sierakowska, H.; Agrawal, S. & Kole, R. (2000). Antisense oligonucleotides as modulators of 
pre-mRNA splicing. Methods Mol.Biol., Vol.133, pp. 223-233 
Sima, N.; Wang, W.; Kong, D.; Deng, D.; Xu, Q.; Zhou, J.; Xu, G.; Meng, L.; Lu, Y.; Wang, S. 
& Ma, D. (2008). RNA interference against HPV16 E7 oncogene leads to viral E6 
and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb 
and p53. Apoptosis., Vol.13, pp. 273-281 
Sivori, S.; Falco, M.; Della, C. M.; Carlomagno, S.; Vitale, M.; Moretta, L. & Moretta, A. 
(2004). CpG and double-stranded RNA trigger human NK cells by Toll-like 
receptors: induction of cytokine release and cytotoxicity against tumors and 
dendritic cells. Proc.Natl.Acad.Sci.U.S.A., Vol.101, pp. 10116-10121 
Smotkin, D.; Prokoph, H. & Wettstein, F. O. (1989). Oncogenic and nononcogenic human 
genital papillomaviruses generate the E7 mRNA by different mechanisms. J.Virol., 
Vol.63, pp. 1441-1447 
Sorensen, D.R.; Leirdal, M. & Sioud, M. (2003). Gene silencing by systemic delivery of 
synthetic siRNAs in adult mice. J.Mol.Biol., Vol.327, pp. 761-766 
Stanley, M. (2010). Pathology and epidemiology of HPV infection in females. Gynecol.Oncol., 
Vol.117, pp. S5-S10 
Steele, C.; Cowsert, L. M. & Shillitoe, E. J. (1993). Effects of human papillomavirus type 18-
specific antisense oligonucleotides on the transformed phenotype of human 
carcinoma cell lines. Cancer Res., Vol.53, pp. 2330-2337 
Sternberger, M.; Schmiedeknecht, A.; Kretschmer, A.; Gebhardt, F.; Leenders, F.; Czauderna, 
F.; von, C., I; Engle, M.; Giese, K.; Beigelman, L. & Klippel, A. (2002). GeneBlocs are 
powerful tools to study and delineate signal transduction processes that regulate 
cell growth and transformation. Antisense.Nucleic.Acid.Drug Dev., Vol.12, pp. 131-
143 
Stojanovic, M.N.; Semova, S.; Kolpashchikov, D.; Macdonald, J.; Morgan, C. & Stefanovic, D. 
(2005). Deoxyribozyme-based ligase logic gates and their initial circuits. 
J.Am.Chem.Soc., Vol.127, pp. 6914-6915 
Takamori, K.; Kubo, T.; Zhelev, Z.; Rumiana, B.; Ohba, H.; Doi, K. & Fujii, M. (2005). 
Suppression of bcr/abl chimeric gene by conjugate DNA enzymes in human cells. 
Nucleic.Acids.Symp.Ser.(Oxf.)., Vol.333-334 
Tan, T.M. & Ting, R. C. (1995). In vitro and in vivo inhibition of human papillomavirus type 
16 E6 and E7 genes. Cancer Res., Vol.55, pp. 4599-4605 
Tang, S.; Tao, M.; McCoy, J. P. J. & Zheng, Z. M. (2006). Short-term induction and long-term 
suppression of HPV16 oncogene silencing by RNA interference in cervical cancer 
cells. Oncogene., Vol.25, pp. 2094-2104 
Toscano-Garibay, J.D.; Benitez-Hess, M. L. & Alvarez-Salas, L. M. (2011). Isolation and 
characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch.Med.Res., 
Vol.42, pp. 88-96 
Tuerk, C. & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: 
RNA ligands to bacteriophage T4 DNA polymerase. Science, Vol.249, pp. 505-510 
Tungteakkhun, S.S.; Filippova, M.; Fodor, N. & Duerksen-Hughes, P. J. (2010). The full-
length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to 
www.intechopen.com
 
Oligonucleotide Applications for the Therapy and Diagnosis of Human Papillomavirus Infection 121 
different sites on the procaspase 8 death effector domain. J.Virol., Vol.84, pp. 1453-
1463 
Uhlenbeck, O.C. (1987). A small catalytic oligoribonucleotide. Nature., Vol.328, pp. 596-600 
Ui-Tei, K.; Naito, Y.; Zenno, S.; Nishi, K.; Yamato, K.; Takahashi, F.; Juni, A. & Saigo, K. 
(2008). Functional dissection of siRNA sequence by systematic DNA substitution: 
modified siRNA with a DNA seed arm is a powerful tool for mammalian gene 
silencing with significantly reduced off-target effect. Nucleic Acids Res., Vol.36, pp. 
2136-2151 
Vaish, N.K.; Kore, A. R. & Eckstein, F. (1998). Recent developments in the hammerhead 
ribozyme field. Nucleic.Acids Res., Vol.26, pp. 5237-5242 
Valencia-Sanchez, M.A.; Liu, J.; Hannon, G. J. & Parker, R. (2006). Control of translation and 
mRNA degradation by miRNAs and siRNAs. Genes Dev., Vol.20, pp. 515-524 
Vasquez, K.M. & Glazer, P. M. (2002). Triplex-forming oligonucleotides: principles and 
applications. Q.Rev.Biophys., Vol.35, pp. 89-107 
Venturini, F.; Braspenning, J.; Homann, M.; Gissmann, L. & Sczakiel, G. (1999). Kinetic 
selection of HPV 16 E6/E7-directed antisense nucleic acids: anti-proliferative 
effects on HPV 16-transformed cells. Nucleic Acids Res., Vol.27, pp. 1585-1592 
Vernon, S.D.; Unger, E. R.; Miller, D. L.; Lee, D. R. & Reeves, W. C. (1997). Association of 
human papillomavirus type 16 integration in the E2 gene with poor disease-free 
survival from cervical cancer. Int.J.Cancer, Vol.74, pp. 50-56 
von Knebel Doeberitz, M. & Gissmann, L. (1987). Analysis of the biological role of human 
papilloma virus (HPV)- encoded transcripts in cervical carcinoma cells by antisense 
RNA. Hamatol.Bluttransfus., Vol.31, pp. 377-379 
von Knebel, D.; Oltersdorf, T.; Schwarz, E. & Gissmann, L. (1988). Correlation of modified 
human papilloma virus early gene expression with altered growth properties in 
C4-1 cervical carcinoma cells. Cancer Res., Vol.48, pp. 3780-3786 
Wagner, R.W.; Matteucci, M. D.; Lewis, J. G.; Gutierrez, A. J.; Moulds, C. & Froehler, B. C. 
(1993). Antisense gene inhibition by oligonucleotides containing C-5 propyne 
pyrimidines. Science, Vol.260, pp. 1510-1513 
Walter, F.; Murchie, A. I.; Thomson, J. B. & Lilley, D. M. (1998). Structure and activity of the 
hairpin ribozyme in its natural junction conformation: effect of metal ions. 
Biochemistry., Vol.37, pp. 14195-14203 
Wang, J.; Jiang, H. & Liu, F. (2000). In vitro selection of novel RNA ligands that bind human 
cytomegalovirus and block viral infection. RNA., Vol.6, pp. 571-583 
Wang, X.; Meyers, C.; Wang, H. K.; Chow, L. T. & Zheng, Z. M. (2011). Construction of a full 
transcription map of human papillomavirus type 18 during productive viral 
infection. J.Virol., Vol.85, pp. 8080-8092 
Wang, X.; Tang, S.; Le, S. Y.; Lu, R.; Rader, J. S.; Meyers, C. & Zheng, Z. M. (2008). Aberrant 
expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is 
required for cancer cell growth. PLoS.ONE., Vol.3, pp. e2557- 
Wang, X.; Wang, H. K.; McCoy, J. P.; Banerjee, N. S.; Rader, J. S.; Broker, T. R.; Meyers, C.; 
Chow, L. T. & Zheng, Z. M. (2009). Oncogenic HPV infection interrupts the 
expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA., 
Vol.15, pp. 637-647 
Werness, B.A.; Levine, A. J. & Howley, P. M. (1990). Association of human papillomavirus 
types 16 and 18 E6 proteins with p53. Science, Vol.248, pp. 76-79 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 122 
Whitehead, K.A.; Langer, R. & Anderson, D. G. (2009). Knocking down barriers: advances in 
siRNA delivery. Nat.Rev.Drug Discov., Vol.8, pp. 129-138 
Witten, D.; Tibshirani, R.; Gu, S. G.; Fire, A. & Lui, W. O. (2010). Ultra-high throughput 
sequencing-based small RNA discovery and discrete statistical biomarker analysis 
in a collection of cervical tumours and matched controls. BMC.Biol., Vol.8, pp. 58-72 
Wu, S.Y.; Singhania, A.; Burgess, M.; Putral, L. N.; Kirkpatrick, C.; Davies, N. M. & 
McMillan, N. A. (2011). Systemic delivery of E6/7 siRNA using novel lipidic 
particles and its application with cisplatin in cervical cancer mouse models. Gene 
Ther., Vol.18, pp. 14-22 
Xue, Y.; Bellanger, S.; Zhang, W.; Lim, D.; Low, J.; Lunny, D. & Thierry, F. (2010). HPV16 E2 
is an immediate early marker of viral infection, preceding E7 expression in 
precursor structures of cervical carcinoma. Cancer Res., Vol.70, pp. 5316-5325 
Yamato, K.; Egawa, N.; Endo, S.; Ui-Tei, K.; Yamada, T.; Saigo, K.; Hyodo, I.; Kiyono, T. & 
Nakagawa, I. (2011). Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA 
chimera modification. Cancer Gene Ther., Vol.18, pp. 587-597 
Yamato, K.; Yamada, T.; Kizaki, M.; Ui-Tei, K.; Natori, Y.; Fujino, M.; Nishihara, T.; Ikeda, 
Y.; Nasu, Y.; Saigo, K. & Yoshinouchi, M. (2008). New highly potent and specific E6 
and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther., 
Vol.15, pp. 140-153 
Yan, A.C.; Bell, K. M.; Breeden, M. M. & Ellington, A. D. (2005). Aptamers: prospects in 
therapeutics and biomedicine. Front.Biosci., Vol.10:1802-27., pp. 1802-1827 
Yi, R.; Qin, Y.; Macara, I. G. & Cullen, B. R. (2003). Exportin-5 mediates the nuclear export of 
pre-microRNAs and short hairpin RNAs. Genes Dev., Vol.17, pp. 3011-3016 
Yoshinouchi, M.; Yamada, T.; Kizaki, M.; Fen, J.; Koseki, T.; Ikeda, Y.; Nishihara, T. & 
Yamato, K. (2003). In vitro and in vivo growth suppression of human 
papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol.Ther., Vol.8, pp. 
762-768 
Yu, Q. & Burke, J. M. (1997). Design of hairpin ribozymes for in vitro and cellular 
applications. Methods Mol.Biol., Vol.74, pp. 161-169 
Zerfass-Thome, K.; Zwerschke, W.; Mannhardt, B.; Tindle, R.; Botz, J. W. & Jansen-Durr, P. 
(1996). Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 
16 E7 oncoprotein. Oncogene, Vol.13, pp. 2323-2330 
Zhang, L.; Han, B.; Li, T. & Wang, E. (2011). Label-free DNAzyme-based fluorescing 
molecular switch for sensitive and selective detection of lead ions. 
Chem.Commun.(Camb.)., Vol.47, pp. 3099-3101 
Zhao, M.X.; Li, J. M.; Du, L.; Tan, C. P.; Xia, Q.; Mao, Z. W. & Ji, L. N. (2011). Targeted 
cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with 
beta-cyclodextrin coupled to amino acids. Chemistry., Vol.17, pp. 5171-5179 
Zheng, Z.M. & Wang, X. (2011). Regulation of cellular miRNA expression by human 
papillomaviruses. Biochim.Biophys.Acta., Vol. 
Zhou, X. & Munger, K. (2009). Expression of the human papillomavirus type 16 E7 
oncoprotein induces an autophagy-related process and sensitizes normal human 
keratinocytes to cell death in response to growth factor deprivation. Virology., 
Vol.385, pp. 192-197 
Zimmermann, H.; Degenkolbe, R.; Bernard, H. U. & O'Connor, M. J. (1999). The human 
papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting 
the transcriptional coactivator CBP/p300. J.Virol., Vol.73, pp. 6209-6219 
www.intechopen.com
Human Papillomavirus and Related Diseases - From Bench to
Bedside - Research aspects
Edited by Dr. Davy Vanden Broeck
ISBN 978-953-307-855-7
Hard cover, 406 pages
Publisher InTech
Published online 25, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cervical cancer is the second most prevalent cancer among women worldwide, and infection with Human
Papilloma Virus (HPV) has been identified as the causal agent for this condition. The natural history of cervical
cancer is characterized by slow disease progression, rendering the condition, in essence, preventable and
even treatable when diagnosed in early stages. Pap smear and the recently introduced prophylactic vaccines
are the most prominent prevention options, but despite the availability of these primary and secondary
screening tools, the global burden of disease is unfortunately still very high. This book will focus on
epidemiological and fundamental research aspects in the area of HPV, and it will update those working in this
fast-progressing field with the latest information.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
María L. Benítez-Hess, Julia D. Toscano-Garibay and Luis M. Alvarez-Salas (2012). Oligonucleotide
Applications for the Therapy and Diagnosis of Human Papillomavirus Infection, Human Papillomavirus and
Related Diseases - From Bench to Bedside - Research aspects, Dr. Davy Vanden Broeck (Ed.), ISBN: 978-
953-307-855-7, InTech, Available from: http://www.intechopen.com/books/human-papillomavirus-and-related-
diseases-from-bench-to-bedside-research-aspects/oligonucleotide-applications-for-the-therapy-and-diagnosis-
of-human-papillomavirus-infection
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
